Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure

References

• Palmieri V, Tracy RP, Roman MJ et al.; Strong Heart Study. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with Type 2 diabetes: the strong heart study. Diabetes Care 26(10), 2764–2769 (2003).
   PubMedGoogle Scholar
• Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in Type 2 diabetes: an update. Diabetes Care 27(8), 1879–1884 (2004).
   PubMed Web of Science ®Google Scholar
• Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 38(2), 421–428 (2001).
   PubMed Web of Science ®Google Scholar
• Jaarsma T, van der Wal MH, Lesman-Leegte I et al.; Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch. Intern. Med. 168(3), 316–324 (2008).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Teerlink JR, Cotter G et al.; VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298(17), 2009–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Palmieri V, Bella JN, Arnett DK et al. Effect of Type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 103(1), 102–107 (2001).
   PubMed Web of Science ®Google Scholar
• Bella JN, Devereux RB, Roman MJ et al. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am. J. Cardiol. 87(11), 1260–1265 (2001).
   PubMed Web of Science ®Google Scholar
• Genda A, Mizuno S, Nunoda S et al. Clinical studies on diabetic myocardial disease using exercise testing with myocardial scintigraphy and endomyocardial biopsy. Clin. Cardiol. 9(8), 375–382 (1986).
   PubMedGoogle Scholar
• Seferovic PM, Milinkovic I, Ristic AD et al. Diabetic cardiomyopathy: ongoing controversies in 2012. Herz 37(8), 880–886 (2012).
   PubMedGoogle Scholar
• Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol. Cell. Biochem. 180(1–2), 53–57 (1998).
   PubMed Web of Science ®Google Scholar
• Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42(7), 1017–1025 (1993).
   PubMed Web of Science ®Google Scholar
• van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 82(3), 848–855 (1990).
   PubMed Web of Science ®Google Scholar
• From AM, Scott CG, Chen HH. Changes in diastolic dysfunction in diabetes mellitus over time. Am. J. Cardiol. 103(10), 1463–1466 (2009).
   PubMed Web of Science ®Google Scholar
• Henry RM, Paulus WJ, Kamp O et al. Deteriorating glucose tolerance status is associated with left ventricular dysfunction–the Hoorn Study. Neth. J. Med. 66(3), 110–117 (2008).
   PubMedGoogle Scholar
• Seferović Mitrović JP, Seferovic PM, Vujisic Tešic B et al. Predictors of diabetic cardiomyopathy in asymptomatic patients with Type 2 diabetes. Int. J. Cardiol. 156(2), 219–221 (2012).
   PubMedGoogle Scholar
• Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25(4), 543–567 (2004).
   PubMed Web of Science ®Google Scholar
• Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled Type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24(1), 5–10 (2001).
   PubMed Web of Science ®Google Scholar
• Magnusson M, Jovinge S, Shahgaldi K, Israelsson B, Groop L, Melander O. Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic Type 2 diabetes patients. Cardiovasc. Diabetol. 9, 2 (2010).
   PubMedGoogle Scholar
• Romano S, Di Mauro M, Fratini S et al. Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovasc. Diabetol. 9, 89 (2010).
   PubMedGoogle Scholar
• Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of early diabetic myocardial disease. J. Am. Coll. Cardiol. 41(4), 611–617 (2003).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens. 16(11 Pt 1), 895–899 (2003).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292(19), 2350–2356 (2004).
   PubMed Web of Science ®Google Scholar
• Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 309(6964), 1286–1291 (1994).
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1), 1–12 (1996).
   PubMedGoogle Scholar
• Bauml MA, Underwood DA. Left ventricular hypertrophy: an overlooked cardiovascular risk factor. Cleve. Clin. J. Med. 77(6), 381–387 (2010).
   PubMedGoogle Scholar
• Dawson A, Rana BS, Pringle SD, Donnelly LA, Morris AD, Struthers AD. How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? J. Hypertens. 22(7), 1403–1408 (2004).
   PubMed Web of Science ®Google Scholar
• Casale PN, Devereux RB, Kligfield P et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J. Am. Coll. Cardiol. 6(3), 572–580 (1985).
   PubMed Web of Science ®Google Scholar
• Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J. Am. Coll. Cardiol. 20(5), 1180–1186 (1992).
   PubMed Web of Science ®Google Scholar
• Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am. Heart J. 37(2), 161–186 (1949).
   PubMed Web of Science ®Google Scholar
• Romhilt DW, Estes EH Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am. Heart J. 75(6), 752–758 (1968).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57(6), 450–458 (1986).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB et al.; American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur. J. Echocardiogr. 7(2), 79–108 (2006).
   PubMed Web of Science ®Google Scholar
• Muiesan ML, Salvetti M, Monteduro C et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 43(4), 731–738 (2004).
   PubMed Web of Science ®Google Scholar
• Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am. J. Hypertens. 8(3), 221–228 (1995).
   PubMed Web of Science ®Google Scholar
• Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 76(3), 232–237 (1996).
   PubMed Web of Science ®Google Scholar
• Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with Type 2 diabetes without overt cardiovascular disease. Diabetes Care 27(8), 1929–1935 (2004).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115(1), 41–46 (2003).
   PubMed Web of Science ®Google Scholar
• Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J. Am. Coll. Cardiol. 43(11), 2116–2123 (2004).
   PubMed Web of Science ®Google Scholar
• Yilmaz R, Altun B, Kahraman S, Ozer N, Akinci D, Turgan C. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Ren. Fail. 32(8), 903–912 (2010).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J. Renin. Angiotensin. Aldosterone. Seyst. 7(4), 236–242 (2006).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, Echarri R, Barrios S, Navarro-Cid J. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. J. Renin. Angiotensin. Aldosterone. Syst. 10(3), 168–173 (2009).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Lonn E, Shaikholeslami R, Yi Q et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J. Am. Coll. Cardiol. 43(12), 2200–2206 (2004).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlöf B et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Gerdts E et al.; LIFE Study Investigators. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 113(12), 1588–1596 (2006).
   PubMedGoogle Scholar
• Devereux RB, Palmieri V, Sharpe N et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 104(11), 1248–1254 (2001).
   PubMed Web of Science ®Google Scholar
• Reichek N, Devereux RB, Rocha RA et al. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Hypertension 54(4), 731–737 (2009).
   PubMed Web of Science ®Google Scholar
• Scognamiglio R, Nosadini R, Marin M et al. Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive Type 2 diabetic patients. Diabetes Care 20(8), 1290–1292 (1997).
   PubMedGoogle Scholar
• Rosendorff C, Dubiel R, Xu J, Chavanu KJ. Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. Am. J. Cardiol. 104(3), 359–365 (2009).
   PubMedGoogle Scholar
• Iwashima Y, Okada M, Haneda M, Yoshida T. Regression of cardiac hypertrophy in Type 2 diabetes with hypertension by candesartan. Diabetes Res. Clin. Pract. 74(1), 8–14 (2006).
   PubMedGoogle Scholar
• Fogari R, Mugellini A, Destro M et al. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. Diabet. Med. 29(1), 24–31 (2012).
   PubMedGoogle Scholar
• The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Cowan BR, Young AA, Anderson C et al.; ONTARGET Investigators. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am. J. Cardiol. 104(11), 1484–1489 (2009).
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Mugellini A, Maffioli P, Preti P, Derosa G. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opin. Pharmacother. 13(8), 1091–1099 (2012).
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59(1), 8–13 (1979).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick JN, St John Sutton M. Assessment of ventricular remodeling in heart failure clinical trials. Curr. Heart Fail. Rep. 9(4), 328–336 (2012).
   PubMedGoogle Scholar
• Derosa G, Maffioli P. Drug safety evaluation of amlodipine. Expert Opin. Drug Saf. 10(5), 795–804 (2011).
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev. Cardiovasc. Ther. 8(6), 835–843 (2010).
   PubMedGoogle Scholar
• Fogari R, Preti P, Zoppi A et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive Type 2 diabetic patients. Am. J. Hypertens. 15(12), 1042–1049 (2002).
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Zoppi A et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am. J. Hypertens. 20(4), 417–422 (2007).
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Carbone A et al. Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clin. Exp. Hypertens. doi:10.3109/10641963.2012.721841 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Derosa G, Cicero AF, Carbone A et al. Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. J. Clin. Pharm. Ther. 38(1), 48–55 (2013).
   PubMedGoogle Scholar
• Derosa G, Cicero AF, Carbone A et al. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. J. Am. Soc. Hypertens. 7(1), 32–39 (2013).
   PubMedGoogle Scholar